How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,983 results for

Chronic Constipation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis

Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis Linaclotide and plecanatide are guanylate cyclase-C (GCC) agonists for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Our objective is to evaluate the efficacy and tolerability of GCC agonists based on data from multiple randomized controlled trials (RCTs

2018 EvidenceUpdates

2. Prucalopride (Resolor) and chronic constipation in men

Prucalopride (Resolor) and chronic constipation in men Prescrire IN ENGLISH - Spotlight ''In the October issue of Prescrire International: Prucalopride (Resolor°) and chronic constipation in men'', 1 October 2016 {1} {1} {1} | | > > > In the October issue of Prescrire International: Prucalopride (Resolor°) and chronic constipation in men Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight In the October issue of Prescrire International: Prucalopride (Resolor°) and chronic constipation in men FREE DOWNLOAD For men presenting with constipation, a troublesome but usually benign disorder, prucalopride carries a disproportionate risk of cardiovascular disorders, depression and suicidal ideation. As in women, it is better to optimise the use of standard laxatives, and to avoid prucalopride altogether. Full text available for free download. Summary

2016 Prescrire

3. Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases) Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2018 Clinical Trials

4. Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain

Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain Oral methylnaltrexone was shown to be effective in treating opioid-induced constipation (OIC) in patients with chronic noncancer pain in a Phase III randomized controlled trial. This report provides a detailed safety analysis from that study.Adults (n=803) with chronic noncancer pain for ≥2 months and confirmed OIC while receiving opioid doses ≥50 mg morphine equivalent per day for ≥14 days (...) generally small and similar across treatment groups. Rescue-laxative use was more common with placebo than methylnaltrexone 450 mg (6.20% vs 4.27% of study days, P=0.024). Changes in opioid dose, OOWS and SOWS scores, and pain-intensity scores during treatment were minimal.Oral methylnaltrexone had a safety profile comparable with placebo in the treatment of OIC in patients with chronic noncancer pain, with no evidence of cardiac toxicity or opioid withdrawal.

2019 EvidenceUpdates

5. Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation (PubMed)

Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation We evaluated the distribution of lower and upper gastrointestinal (GI) symptoms among individuals with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in a nationwide survey.Individuals (≥ 18 years of age) were identified from a nationwide sample of > 70 000 United States adults. Participants (...) adults met eligibility criteria (275 with IBS-C, 734 with CIC). Demographics were similar among groups except for education, marital and employment status, and income. Adjusting for demographic differences, GI-PROMIS scores of global GI symptoms were higher in IBS-C (251.1; 95% CI, 230.0-273.1) compared to CIC (177.8; 95% CI 167.2-188.4) (P < 0.001). Abdominal pain was more prevalent (OR, 4.3; 95% CI, 2.9-6.6) and more severe (P = 0.007) in IBS-C. Constipation was more severe in IBS-C (P = 0.011

Full Text available with Trip Pro

2018 Journal of neurogastroenterology and motility

6. Plecanatide (Trulance) for Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation (PubMed)

Plecanatide (Trulance) for Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation.

Full Text available with Trip Pro

2018 Pharmacy and Therapeutics

7. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. (PubMed)

Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. Linaclotide and plecanatide are guanylate cyclase-C (GCC) agonists for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Our objective is to evaluate the efficacy and tolerability of GCC agonists based on data from multiple randomized controlled trials

2018 American Journal of Gastroenterology

8. Effects of psyllium vs. placebo on constipation, weight, glycemia, and lipids: A randomized trial in patients with type 2 diabetes and chronic constipation. (PubMed)

Effects of psyllium vs. placebo on constipation, weight, glycemia, and lipids: A randomized trial in patients with type 2 diabetes and chronic constipation. To compare the effects of baked psyllium supplementation versus those who received a placebo on constipation symptoms, body weight, glycemic and lipids control in patients with type 2 diabetes (T2D) and chronic constipation.In a single-blinded, randomized controlled trial, 51 patients with T2D and chronic constipation with body mass index (...) ) decreased in the psyllium group. The compliance was good and no adverse effects were observed.In patients with T2D and chronic constipation, psyllium supplementation decreased constipation symptoms, body weight, glycemic, cholesterol, and increased HDLC levels.Copyright © 2018 Elsevier Ltd. All rights reserved.

2018 Complementary Therapies In Medicine Controlled trial quality: uncertain

9. The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation (PubMed)

The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation The objective of this study was to evaluate the cost effectiveness of lubiprostone, prucalopride, placebo and immediate referral to secondary care in chronic idiopathic constipation (CIC) in an economic model that was used by the UK National Institute for Health and Care Excellence (NICE) in developing guidance.We developed a cohort state-transition model to reflect the treatment pathway in CIC from the UK NHS

Full Text available with Trip Pro

2018 PharmacoEconomics open

10. Prucalopride (Motegrity) - To treat chronic idiopathic constipation

Prucalopride (Motegrity) - To treat chronic idiopathic constipation Drug Approval Package: Motegrity (prucalopride) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Motegrity (prucalopride) Company: Shire Development LLC Application Number: 210166 Approval Date: 12/14/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2019 FDA - Drug Approval Package

11. Biofeedback for treatment of chronic idiopathic constipation in adults. (PubMed)

Biofeedback for treatment of chronic idiopathic constipation in adults. Biofeedback therapy has been used to treat the symptoms of people with chronic constipation referred to specialist services within secondary and tertiary care settings. However, different methods of biofeedback are used within different centres and the magnitude of suggested benefits and comparable effectiveness of different methods of biofeedback has yet to be established.To determine the efficacy and safety of biofeedback (...) for the treatment of chronic idiopathic (functional) constipation in adults.We searched the following databases from inception to 16 December 2013: CENTRAL, the Cochrane Complementary Medicine Field, the Cochrane IBD/FBD Review Group Specialized Register, MEDLINE, EMBASE, CINAHL, British Nursing Index, and PsychINFO. Hand searching of conference proceedings and the reference lists of relevant articles was also undertaken.All randomised trials evaluating biofeedback in adults with chronic idiopathic constipation

Full Text available with Trip Pro

2014 Cochrane

12. The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03054506 Recruitment Status : Completed First Posted : February 15, 2017 Last Update Posted : March 6

2017 Clinical Trials

13. Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents (PubMed)

Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents Background. Chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C) are common functional lower gastrointestinal disorders that impair patients' quality of life. In a national survey, we aimed to evaluate (1) Canadian physician practice patterns

Full Text available with Trip Pro

2017 Canadian journal of gastroenterology & hepatology

14. To explore the effects of medical and lifestyle interventions on constipation for patients with chronic kidney disease

To explore the effects of medical and lifestyle interventions on constipation for patients with chronic kidney disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

15. Placebo response rate in patients with chronic constipation

Placebo response rate in patients with chronic constipation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

16. Constipation in children

to excessive hardening of the stool. This often starts as an acute problem but can progress to faecal impaction and chronic constipation. Particularly in young children, any cause of painful defecation may provoke active withholding. Withholding may worsen the constipation and lead to a vicious cycle. Duration of constipation and amount of stool burden may depend on capacity of the child's rectum, the degree of megarectum, and other factors including rectal sensory function. After faecal disimpaction (...) Constipation in children Constipation in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Constipation in children Last reviewed: February 2019 Last updated: February 2019 Summary Childhood constipation is typically characterised by infrequent bowel evacuations, large stools, and difficult or painful defecation. Symptoms may result from low fibre, poor nutrient, and/or insufficient water intake, which leads

2019 BMJ Best Practice

17. Prevalence of Chronic Constipation and Chronic Diarrhea in Diabetic Individuals in the United States. (PubMed)

Prevalence of Chronic Constipation and Chronic Diarrhea in Diabetic Individuals in the United States. Diabetic individuals commonly report disordered bowel habits. This study aims to report the prevalence and associated factors of chronic diarrhea (CD) and chronic constipation (CC) in diabetics using a nationally representative sample of US adults.Analyses were performed using data from subjects in the 2009-2010 National Health and Nutrition Examination Survey (NHANES) dataset who completed

2018 American Journal of Gastroenterology

18. Naldemedine (Rizmoic) - treating constipation caused by opioid pain relief medicines

Naldemedine (Rizmoic) - treating constipation caused by opioid pain relief medicines 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/21684/2019 EMEA/H/C/004256 Rizmoic An overview of Rizmoic and why it is authorised in the EU (...) What is Rizmoic and what is it used for? Rizmoic is a medicine for treating constipation caused by opioid pain relief medicines in patients who have previously been treated with a laxative (a medicine that triggers bowel movements). It contains the active substance naldemedine. How is Rizmoic used? Rizmoic is available as 200 microgram tablets. The recommended dose is one tablet once daily, which the patient can take with or without a laxative. The patient must stop taking Rizmoic when

2019 European Medicines Agency - EPARs

19. Contribution of Sensory Processing to Chronic Constipation in Preschool Children. (PubMed)

Contribution of Sensory Processing to Chronic Constipation in Preschool Children. To assess differences in sensory processing patterns between children with chronic constipation compared with a matched normative sample as well as to examine the extent to which specific sensory processing patterns and modality scores predicted atypical toileting behaviors.We used a cross-sectional comparative design to evaluate differences between children age 3 and 5 years old with constipation (n = 66 (...) ) and those in a matched control sample (n = 66). We also examined the contribution of sensory processing patterns to atypical toileting behavior in the clinical sample.Children with chronic constipation showed significantly higher sensory scores than a matched normative sample, specifically in oral processing (P < .001), visual processing (P < . 05), sensory avoiding (P < .001), and sensory sensitivity (P < .05). Sensory registration, avoidance, and oral processing significantly predicted toileting

Full Text available with Trip Pro

2019 Journal of Pediatrics

20. Chronic Constipation. (PubMed)

Chronic Constipation. Constipation is a common symptom that may be primary (idiopathic or functional) or associated with a number of disorders or medications. Although most constipation is self-managed by patients, 22% seek health care, mostly to primary care physicians (>50%) and gastroenterologists (14%), resulting in large expenditures for diagnostic testing and treatments. There is strong evidence that stimulant and osmotic laxatives, intestinal secretagogues, and peripherally restricted μ (...) -opiate antagonists are effective and safe; the lattermost drugs are a major advance for managing opioid-induced constipation. Constipation that is refractory to available laxatives should be evaluated for defecatory disorders and slow-transit constipation using studies of anorectal function and colonic transit. Defecatory disorders are often responsive to biofeedback therapies, whereas slow-transit constipation may require surgical intervention in selected patients. Both efficacy and cost should

Full Text available with Trip Pro

2019 Mayo Clinic Proceedings

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>